A top pharmaceutical executive at a well-known pharmaceutical company has resigned.

Pharmaceutical Network September 2 - August 31, Essence Pharmaceuticals issued an announcement. on August 27, 2020, the Board of Directors of
received a written resignation report from Mr. Zhu Chunlin and Mr. Yang Xiaojun, who applied to resign as a director of the Company for personal reasons, and Mr. Yang Xiaojun, who applied to resign as a director and deputy general manager of the Company for personal reasons.
Mr. Zhu Chunlin resigned from any position in the company, and Mr. Yang Xiaojun resigned and continued to serve as chairman of Bao hetang Pharmaceutical Co., Ltd., a subsidiary of the company.
In fact, Zhu Chunlin, as a former chairman, announced his resignation on April 22, 2019, resigning as chairman of the company due to his personal health and age, and resigning as a member of the nomination committee, audit committee and strategy committee of the company's fourth board of directors.
data show that Zhu Chunlin was the deputy director of Nantong Pesticide Factory, the director of the technical center, the general manager of Nantong Jiangshan Pesticide Chemical Co., Ltd., the deputy general manager of the essence group, the deputy general manager of Nantong Industry and Trade, and the chairman of Nantong Essence Pharmaceutical Co., Ltd.
resignation, Zhu Chunlin, the former chairman, has continued to reduce his holdings, accounting for 0.21% of the outstanding share capital, cashing out more than 10 million yuan.
the impact of his resignation, Essential Pharmaceuticals began to fall after April 22, falling more than 15 per cent in seven trading days.
Zhu Chunlin now thoroughly cut with the essence of pharmaceutical, no longer hold any position, the future of how to go, worthy of follow-up attention.
performance from the profit and loss of the essence of the pharmaceutical industry for the pharmaceutical manufacturing industry, the main business for traditional Traditional Chinese medicine preparations, chemical raw materials and intermediates, chemical medicine intermediates, Chinese herbal medicine and Chinese medicine tablets, biopharmaceuticals, such as research and development, production and sales.
Exclusive products are the superiority of the variety of essence pharmaceutical, the company's traditional Chinese medicine products Wang's Bao Chi Pill, Ji Desheng snake pills for the exclusive varieties, and Wang's Bao Chi Pill and Ji Desheng Snake pills are listed as the national Chinese medicine confidential varieties, of which Ji Desheng snake pills are listed as top secret;
Among them, respiratory diseases are the main areas of the essence of pharmaceutical products, such as Wang's Bao Chi Pill clinical mainly used in children, adult digestive diseases and children's respiratory diseases, ZhengchaiHu drinking particle prescription from the Ming Dynasty famous doctor Zhang Jingyue "King Yue Book" to dissipate the representative side of the "Chaihu drink", the last century by the Chinese Academy of Traditional Chinese Medicine fully researched and developed the treatment of colds of chinese medicine.
, the impact of the new crown outbreak on the essence of pharmaceutical is relatively large.
On the evening of August 30, Essence Pharmaceuticals released its semi-annual results report that net income attributable to shareholders of listed companies in the first half of 2020 was about 104 million yuan, down 19.32% YoY, and operating income was about 607 million yuan, down 4.66% YoY, with underlying earnings per share of 0.1274 yuan, down 19.32% YoY.
company disclosed that during the outbreak, many provinces and cities introduced drugstores to prohibit the sale of cold deheated products, my company is Chaihu drinking particles, Wang's Bao Chi pills, golden buckwheat cereal (capsules) are limited because of the role of treating cold fever, more Shanghai believes that the effect of large Chaihu particles have deheated and restricted use, there are still many regional pharmacies, small clinics prohibit the sale of cold fever drugs.
the outbreak led to a sharp drop in hospital outpatients, from 40%-50% in the first quarter of the same period last year, and slightly higher in May and June, reaching 60%-70%.
, the second outbreak in Beijing has once again led to a decline in outpatient visits, which are now basically stable at around 70%.
the number of drug purchases and sales at pharmacies in The United States has declined sharply, and drug sales have decreased by 30-40%, especially as heat-regressing drugs have been severely affected and company sales will be adversely affected.
At the time of Zhu Chunlin's resignation, Essence Pharmaceuticals issued a bright first-quarter 2019 report, reporting revenue of RMB342 million, up 4.84% YoY, and net profit attributable to shareholders of listed companies of RMB67.6138 million, up 12.51% YoY.
due to the impact of the new crown outbreak, the performance of essence pharmaceutical from profit to loss, the former chairman and completely left, the future of the new helm how to deal with the status quo, we wait and see.
dozens of pharmaceutical companies, executive changes, as Essence Pharmaceuticals said, the new crown outbreak has put pressure on the performance of pharmaceutical companies, which invisibly makes drug companies more frequent changes in executives.
addition to Essence Pharmaceuticals, executives from dozens of pharmaceutical companies have left.
August 28, the board of directors of The United States Health Industry Holdings Co., Ltd. announced that the board of directors recently received a written resignation report submitted by Mr. Zhang Shengjiang, Vice President of the Company, and applied to resign as Vice President of the Company due to work adjustment arrangements.
August 25, the board of directors of Xinbang Pharmaceuticals received written resignation reports from the directors of the company, Mr. Xiang Li and Ms. Xu Qi.
Xiang Li applied to resign as a director and vice chairman of the company for personal reasons, and also resigned as a member of the Strategic Committee of the Board of Directors, and Ms. Xu Qi applied to resign as a director of the company for personal reasons.
August 19, Jingfeng Pharmaceuticals said that Mr. Zhang Junguo had applied for his resignation as the company's director of human resources and various positions in the company's subsidiaries for personal reasons.
same day, Geelyde's global vice president and general manager of China, Luo Yongqing, decided to leave the company and seek external development.
August 17th, Fuzheng Pharmaceuticals announced that Mr. Sun Jilin had resigned as chairman and general manager of the company for personal reasons, effective August 10, 2020.
August 11, Step Pharmaceuticals announced that Ms. Wang Mei had applied to resign as the company's supervisor for personal reasons and would not hold any position in the company after her resignation.
Ms. Wang Mei's resignation report will take effect when it reaches the Supervisory Board.
August 10, Tonghua Dongbao announced that Mr. Han Fengjun had applied to resign as deputy general manager of the company for personal reasons.
same day, Anhui Huangshan Capsules announced that Mr. Zhang Min had applied to resign as an independent director of the company and as a special committee under the board of directors because his term of office had expired.
August 7, the board of directors of Gansu Shenyi Pharmaceuticals received a written resignation from Mr. Qian Shuangxi, Deputy General Manager of the company.
Mr. Qian Shuangxi due to personal work changes, another appointment, applied to resign as deputy general manager of the company, Mr. Qian Shuangxi resigned will no longer hold any position in the company.
August 6, Seven Dan Pharmaceuticals announced that Mr. Zhang Hadson had resigned as the company's supervisor for personal reasons.
August 3, Nanjing Pharmaceuticals announced that Mr. Han Dong had applied to resign as a director of the company's 8th board of directors, a member of the audit and risk control committee of the board of directors, and that Mr. Han Dong would not hold any position in the company after his resignation.
.